AU2014332960B2 - Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative - Google Patents

Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative Download PDF

Info

Publication number
AU2014332960B2
AU2014332960B2 AU2014332960A AU2014332960A AU2014332960B2 AU 2014332960 B2 AU2014332960 B2 AU 2014332960B2 AU 2014332960 A AU2014332960 A AU 2014332960A AU 2014332960 A AU2014332960 A AU 2014332960A AU 2014332960 B2 AU2014332960 B2 AU 2014332960B2
Authority
AU
Australia
Prior art keywords
vii
compound represented
formula
crystalline form
chemical formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014332960A
Other languages
English (en)
Other versions
AU2014332960A1 (en
Inventor
Takao Abe
Takeshi Furuuchi
Nakako Mitsuhashi
Yumiko Saito
Yoshiaki Sakamaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meiji Seika Pharma Co Ltd
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AU2014332960A1 publication Critical patent/AU2014332960A1/en
Application granted granted Critical
Publication of AU2014332960B2 publication Critical patent/AU2014332960B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014332960A 2013-10-08 2014-10-08 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative Ceased AU2014332960B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-211242 2013-10-08
JP2013211242 2013-10-08
PCT/JP2014/076875 WO2015053297A1 (ja) 2013-10-08 2014-10-08 ジアザビシクロオクタン誘導体の結晶とその製造法

Publications (2)

Publication Number Publication Date
AU2014332960A1 AU2014332960A1 (en) 2016-05-26
AU2014332960B2 true AU2014332960B2 (en) 2018-03-29

Family

ID=52813113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014332960A Ceased AU2014332960B2 (en) 2013-10-08 2014-10-08 Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative

Country Status (22)

Country Link
US (5) US10131665B2 (enExample)
EP (4) EP3067355B1 (enExample)
JP (3) JP6617029B2 (enExample)
KR (2) KR102487297B1 (enExample)
CN (2) CN105612159A (enExample)
AR (4) AR097971A1 (enExample)
AU (1) AU2014332960B2 (enExample)
BR (2) BR122022016622B1 (enExample)
CA (2) CA3110803C (enExample)
DK (1) DK3067355T3 (enExample)
ES (2) ES2842225T3 (enExample)
HK (1) HK1219479A1 (enExample)
HU (1) HUE051925T2 (enExample)
IL (2) IL244969B (enExample)
MX (2) MX361659B (enExample)
MY (1) MY199066A (enExample)
NZ (5) NZ757221A (enExample)
RU (1) RU2695219C2 (enExample)
SG (1) SG11201602723RA (enExample)
TW (1) TWI673269B (enExample)
WO (1) WO2015053297A1 (enExample)
ZA (1) ZA201602054B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117734C2 (uk) 2012-05-30 2018-09-25 Мейдзі Сейка Фарма Ко., Лтд. НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
NZ757221A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
BR112017010445B8 (pt) * 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
SG11202000217QA (en) 2017-07-21 2020-02-27 Antabio Sas Chemical compounds
KR20200091396A (ko) 2017-09-27 2020-07-30 페도라 파마슈티칼스 인코포레이티드 디아자비시클로옥탄 유도체의 약제학적 형태 및 그의 제조 방법
CA3076959C (en) * 2017-09-27 2025-02-11 Meiji Seika Pharma Co., Ltd. CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND THEIR PRODUCTION PROCESS
TW201920174A (zh) * 2017-09-27 2019-06-01 瑞士商羅氏大藥廠股份有限公司 二氮雜雙環辛烷衍生物之醫藥形式及其製法
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
US11897844B2 (en) * 2018-09-21 2024-02-13 Api Corporation Method for producing amino acid derivatives
JP7096957B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US20130225554A1 (en) * 2011-12-02 2013-08-29 Naeja Pharmaceutical Inc. New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (enExample) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (enExample) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
CN1048248C (zh) 1994-05-02 2000-01-12 盐野义制药株式会社 吡咯烷基硫基碳代青霉烯衍生物的结晶、含该结晶的冷冻干燥制剂及其制造方法
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
SI2231667T1 (sl) * 2008-01-18 2013-12-31 Merck Sharp & Dohme Corp. Beta laktamazni inhibitorji
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
CN104892490B (zh) 2010-12-22 2017-07-21 明治制果药业株式会社 用于制备光学活性二氮杂环辛烷衍生物的中间体化合物的化合物
KR101512738B1 (ko) 2011-08-27 2015-04-17 욱크하르트 리미티드 1,6-디아자-비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
JP5677634B2 (ja) 2011-08-30 2015-02-25 ウォックハート リミテッド 1,6−ジアザビシクロ[3,2,1]オクタン−7−オン誘導体および細菌感染の処置におけるそれらの使用
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
UA117734C2 (uk) 2012-05-30 2018-09-25 Мейдзі Сейка Фарма Ко., Лтд. НОВИЙ ІНГІБІТОР β-ЛАКТАМАЗИ І СПОСІБ ЙОГО ОДЕРЖАННЯ
BR112015003592B1 (pt) * 2012-08-25 2020-04-14 Wockhardt Ltd derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infecções bacterianas
MY176278A (en) 2013-09-24 2020-07-27 Meiji Seika Pharma Co Ltd Process for producing diazabicyclooctane derivative and intermediate thereof
NZ757221A (en) 2013-10-08 2021-12-24 Meiji Seika Pharma Co Ltd Crystalline forms of diazabicyclooctane derivative and production process thereof
BR112016022437A2 (pt) 2014-03-29 2017-08-15 Wockhardt Ltd Processo para preparação de (2s,5r)-6-(benziloxi)-7-oxo-1,6- diazabiciclo[3,2,1]octano-2-carboxilato de sódio
BR112017010445B8 (pt) 2014-12-05 2024-02-27 Meiji Seika Pharma Co Ltd Processo de produção de cristais de derivado de diazabiciclo-octano e preparação liofilizada estável

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012172368A1 (en) * 2011-06-17 2012-12-20 Astrazeneca Ab Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof
US20130225554A1 (en) * 2011-12-02 2013-08-29 Naeja Pharmaceutical Inc. New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors

Also Published As

Publication number Publication date
CA3110803C (en) 2022-09-27
US20220348578A1 (en) 2022-11-03
ES2901198T3 (es) 2022-03-21
CN105612159A (zh) 2016-05-25
US12221443B2 (en) 2025-02-11
HK1219479A1 (zh) 2017-04-07
IL244969B (en) 2022-01-01
NZ757220A (en) 2021-12-24
RU2695219C2 (ru) 2019-07-22
EP3067355B1 (en) 2020-12-16
US20190031659A1 (en) 2019-01-31
WO2015053297A1 (ja) 2015-04-16
CA3110803A1 (en) 2015-04-16
AU2014332960A1 (en) 2016-05-26
RU2019115119A3 (enExample) 2022-04-26
KR102388529B1 (ko) 2022-04-20
RU2016116501A (ru) 2017-11-15
EP3613741A1 (en) 2020-02-26
EP3613740A1 (en) 2020-02-26
TW201605855A (zh) 2016-02-16
AR132029A2 (es) 2025-05-21
EP3299370B1 (en) 2021-11-24
EP3067355A1 (en) 2016-09-14
EP3299370A1 (en) 2018-03-28
JP2020007366A (ja) 2020-01-16
MX383661B (es) 2025-03-14
AR097971A1 (es) 2016-04-20
IL289275B2 (en) 2023-02-01
CA2926071A1 (en) 2015-04-16
IL289275B (en) 2022-10-01
JP6617029B2 (ja) 2019-12-04
NZ757221A (en) 2021-12-24
NZ757222A (en) 2021-12-24
IL289275A (en) 2022-02-01
BR112016006266B1 (pt) 2022-11-16
BR122022016622B1 (pt) 2023-11-07
HK1250030A1 (en) 2018-11-23
US20200181143A1 (en) 2020-06-11
JP6995810B2 (ja) 2022-01-17
TWI673269B (zh) 2019-10-01
MX361659B (es) 2018-12-13
ZA201602054B (en) 2019-06-26
US10131665B2 (en) 2018-11-20
RU2016116501A3 (enExample) 2018-07-12
DK3067355T3 (da) 2021-01-04
CA2926071C (en) 2021-11-09
SG11201602723RA (en) 2016-05-30
RU2019115119A (ru) 2019-05-29
CN111153903A (zh) 2020-05-15
HUE051925T2 (hu) 2021-04-28
NZ719568A (en) 2018-06-29
NZ743374A (en) 2021-12-24
US20160272641A1 (en) 2016-09-22
AR132028A2 (es) 2025-05-21
IL244969A0 (en) 2016-05-31
KR102487297B1 (ko) 2023-01-12
KR20220054694A (ko) 2022-05-03
MY199066A (en) 2023-10-12
ES2842225T3 (es) 2021-07-13
AR132030A2 (es) 2025-05-21
KR20160065871A (ko) 2016-06-09
JPWO2015053297A1 (ja) 2017-03-09
MX2016004506A (es) 2016-06-16
US20250059191A1 (en) 2025-02-20
EP3067355A4 (en) 2017-04-26
BR112016006266A2 (enExample) 2017-08-22
JP2021193107A (ja) 2021-12-23
JP7182677B2 (ja) 2022-12-02
US10604522B2 (en) 2020-03-31
US11414417B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
US12221443B2 (en) Crystalline forms of diazabicyclooctane derivative and production process thereof
RU2838718C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2840014C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
RU2847390C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
HK40023145A (en) Preparation of a diazabicyclooctane derivative
HK40023146A (en) Preparation of a diazabicyclooctane derivative
RU2801220C2 (ru) Кристаллические формы производного диазабициклооктана и способ их получения
HK1226731A1 (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
HK1226731B (en) Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
HK40027891A (zh) 二氮杂二环辛烷衍生物的结晶及其制备方法和应用以及医药组合物
HK1250030B (en) Crystalline forms of diazabicyclooctane derivative and production process thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired